Vascular dementia

Topics in Stroke Rehabilitation

Volumn 15, Issue 1, 2008, Pages 22-26

  Schneck, Michael J ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Anticholinesterase inhibitors; Memantine; Vascular dementia

Indexed keywords

ANTICOAGULANT AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMANTINE; NOTCH3 RECEPTOR; RIVASTIGMINE;

ALZHEIMER DISEASE; AMNESIA; BRAIN HEMORRHAGE; BRAIN INFARCTION; CADASIL; CARDIOVASCULAR RISK; CHROMOSOME 19; COGNITION; COGNITIVE DEFECT; DISEASE ASSOCIATION; HUMAN; MULTIINFARCT DEMENTIA; REVIEW; RISK FACTOR; RISK REDUCTION;

AGED; CHOLINESTERASE INHIBITORS; DEMENTIA, MULTI-INFARCT; DEMENTIA, VASCULAR; DIAGNOSIS, DIFFERENTIAL; HUMANS; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS;

EID: 38549141738     PISSN: 10749357     EISSN: None     Source Type: Journal    
DOI: 10.1310/tsr1501-22     Document Type: Review

References (31)

1. Gorelick PB, Roman G, Mangone CA. Vascular dementia. In: Gorelick PB, Alter M, eds. Handbook of Neuroepidemiology. New York: Marcel Dekker; 1994:197-208.
2. Román GC. Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Med Clin North Am. 2002;86:477-499.
3. Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol. 1975;32(9):632-637.
4. O'Neill D, Gerrrard J, Surmon D, Wilcock GK. Variability in scoring the Hachinski Ischaemic Score. Age Ageing. 1995;24(3):242-246.
5. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250-260.
6. Black SE. Vascular dementia: stroke risk and sequelae define therapeutic approaches. Postgrad Med. 2005;117(1):15-25.
7. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1143-1153.
8. Pohjasvaara T, Mantyla R, Ylikoski R, et al. Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia. Stroke. 2000;31(12):2952-2957.
9. Vermeer SE, Prins ND, den Heijer T, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348(13):1215-1222.
10. Farlow MR. Use of antidementia agents in vascular dementia: beyond Alzheimer disease. Mayo Clin Proc. 2006;81(10):1350-1358.
11. Leysa D, Pasquier F, Parnetti L. Epidemiology of vascular dementia. Haemostasis. 1998;28:134-150.
12. Román GC. Vascular dementia may be the most common form of dementia in the elderly. J Neurol Sci. 2002;203-204:7-10.
13. Wolfson C, Wolfson DB, Asgharian M, et al. Clinical Progression of Dementia Study Group. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med. 2001;344(15):1111-1116.
14. Joutel A, Corpechot C, Ducros A, et al. Notch 3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996;383:707-710.
15. in't Veld BA, Ruitenberg A, Hofman A, Stricker BH, Breteler MM. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging. 2001;22(3):407-412.
16. Freels S, Nyenhuis DL, Gorelick PB. Predictors of survival in African American patients with AD, VaD, or stroke without dementia. Neurology. 2002;59:1146-1153.
17. Schneck MJ. "Silent" strokes and dementia. New Engl J Med. 2003;349(1):96.
18. Williams PS, Spector A, Orrell M, Rands G. Aspirin for vascular dementia [update]. Cochrane Database Syst Rev. 2000;(4):CD001296.
19. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al., for the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559.
20. Bernick C, Katz R, Smith NL, et al. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology. 2005;65(9):1388-1394.
21. Rea TD, Breitner JC, Psaty BM, et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol. 2005;62(7):1047-1051.
22. Li G, Higdon R, Kukull WA, et al. Statin therapy and risk of dementia in the elderly: A community-based prospective cohort study. Neurology. 2004;63(9):1624-1628.
23. Zandi PP. Sparks DL. Khachaturian AS. et al., for the Cache County Study Investigators. Do statins reduce risk of incident dementia and Alzheimer disease? Arch Gen Psychiatry. 2005;62(2):217-224.
24. van Dongen MC, van Rossum E, Kessels AG, Sielhorst HJ, Knipschild PG. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J Am Geriatr Soc. 2000;48(10):1183-1194.
25. Black S, Román GC, Geldmacher DS, et al., Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003;34:2323-2330.
26. Wilkinson D, Doody R, Helme R, et al., Donepezil 308 Study Group. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003;61:479-486.
27. Auchus AP, Brashear HR, Salloway S, et al., for the GAL-INT-26 Study Group. Galantamine treatment of vascular dementia: A randomized trial. Neurology. 2007;69(5): 448-458.
28. Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database of Syst Rev. 2004;(1):CD004395.
29. Craig D, Birks J. Rivastigmine for vascular cognitive impairment. Cochrane Database of Syst Rev. 2005;(2):CD004744.
30. Craig D, Birks J. Galantamine for vascular cognitive impairment. Cochrane Database of Syst Rev. 2006;(1):CD004746.
31. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database of Syst Rev. 2006;(2):CD003154.